Non-Invasive Macromolecule Delivery Consortium (NMDC)
At a Glance
- Status: Active Consortium
- Year Launched: 2014
- Initiating Organization: The Catalent Applied Drug Delivery
- Initiator Type: Industry
- No disease focus
- Location: North America
The Non-invasive Macromolecule Delivery Consortium (NMDC) is focused on fostering collaboration and the use of innovative drug delivery technologies to deliver proteins, peptides, and vaccines via non-invasive methods. The NMDC has established 4 working groups focused on oral, pulmonary/nasal, ocular, and transdermal methods of delivering large molecules to patients. The NMDC provides networking opportunities to showcase new approaches, facilitates matchmaking for future research, publications as educational resources and is building a community of practice to advance non-invasive delivery of medications.
The mission of the consortium is to elevate drug delivery techniques to make them more effective and less invasive.
Structure & Governance
The Catalent Applied Drug Delivery Institute (CADDI) established the NMDC.
The consortium is funded by the CADDI
The Catalent Institute’s NMDC was selected as 1 of 30 organizations to present during the Innovator Presentations at the Partnering for Cures conference held in NYC on 11/17/14: http://www.partneringforcures.org/program/agenda/view/5359
The NMDC was invited to participate in the program of the Drug Delivery Partnerships conference taking place on January 29-30, 2015 in Boca Raton, FL.
The Ocular Working Group has been identifying gaps in the current guidance with various regulatory bodies.
We are currently working to identify collaborative research projects for funding/grant submission to address non-invasive delivery solutions for vaccines.
Points of Contact
Sponsors & Partners
University of Bath
St. John’s University
New Jersey Institute of Technology